Biocryst Pharmaceuticals INC: 2 tracked 2026 layoff event(s), 47 workers counted, highest AI score 4.
AI score 4 (80% interval 3–4) · evidence grade D · US · Pharma / Chemicals
Stated reason: On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”). The Plan was approved as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline, following a comprehensive strategic review and sc…
Why 4: Plant, store or site closure · Drivers: contrary evidence −0.6, industry AI exposure +0.5, role AI exposure +0.2
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.761, industry exposure 0.712, AI investment 0.0, contrary 0.4 · named roles: Computer and Information Systems Managers, General and Operations Managers
Headcount basis: not disclosed
AI score 4 (80% interval 3–4) · evidence grade D · AL · Pharma / Chemicals
Stated reason: of the Original Report. The Original Report otherwise remains unchanged. Item 2.05. Costs Associated with Exit or Disposal Activities. On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipel…
Why 4: Plant, store or site closure · Drivers: contrary evidence −0.6, industry AI exposure +0.5, role AI exposure +0.1
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary 0.4 · typical Health Care & Pharma roles (no roles named)
Headcount basis: WARN (sum of state notices; company-wide total not disclosed) · WARN: 47 workers at 1 site notice(s)
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
